Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.

Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T.

Biologicals. 2019 Feb 9. pii: S1045-1056(18)30330-0. doi: 10.1016/j.biologicals.2019.01.007. [Epub ahead of print]

PMID:
30755369
2.

Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland.

Mankinen P, Vihervaara V, Torvinen S, Martikainen J, Soini E.

J Med Econ. 2019 Jan 15:1-8. doi: 10.1080/13696998.2019.1569457. [Epub ahead of print]

PMID:
30644325
3.

Misuse and/or treatment delivery failure of inhalers among patients with asthma or COPD: A review and recommendations for the conduct of future research.

Mahon J, Fitzgerald A, Glanville J, Dekhuijzen R, Glatte J, Glanemann S, Torvinen S.

Respir Med. 2017 Aug;129:98-116. doi: 10.1016/j.rmed.2017.05.004. Epub 2017 May 15. Review.

PMID:
28732842
4.

Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®.

Lewis A, Torvinen S, Dekhuijzen PNR, Chrystyn H, Melani A, Zöllner Y, Kolbe K, Watson AT, Blackney M, Plich A.

Respir Med. 2017 Aug;129:179-188. doi: 10.1016/j.rmed.2017.06.018. Epub 2017 Jun 27.

5.

Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment.

Hawken N, Torvinen S, Neine ME, Amri I, Toumi M, Aballéa S, Plich A, Roche N.

BMC Pulm Med. 2017 Jul 6;17(1):99. doi: 10.1186/s12890-017-0439-x.

6.

Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment.

Bergius S, Torvinen S, Muhonen T, Roine RP, Sintonen H, Taari K.

Scand J Urol. 2017 Feb;51(1):13-19. doi: 10.1080/21681805.2016.1247293. Epub 2016 Nov 4.

PMID:
27809631
7.

The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries.

Lewis A, Torvinen S, Dekhuijzen PN, Chrystyn H, Watson AT, Blackney M, Plich A.

BMC Health Serv Res. 2016 Jul 12;16:251. doi: 10.1186/s12913-016-1482-7.

8.

Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler).

Sandler N, Holländer J, Långström D, Santtila P, Saukkonen A, Torvinen S.

BMJ Open Respir Res. 2016 Mar 22;3(1):e000119. doi: 10.1136/bmjresp-2015-000119. eCollection 2016.

9.

USE OF PATIENT ASSESSED HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS IN PROSTATE CANCER RESEARCH: A SYSTEMATIC REVIEW OF THE LITERATURE 2002-15.

Torvinen S, Bergius S, Roine R, Lodenius L, Sintonen H, Taari K.

Int J Technol Assess Health Care. 2016 Jan;32(3):97-106. doi: 10.1017/S0266462316000118. Epub 2016 Mar 22. Review.

PMID:
27001542
10.

Identification of factors involved in medication compliance: incorrect inhaler technique of asthma treatment leads to poor compliance.

Darbà J, Ramírez G, Sicras A, García-Bujalance L, Torvinen S, Sánchez-de la Rosa R.

Patient Prefer Adherence. 2016 Feb 9;10:135-45. doi: 10.2147/PPA.S95303. eCollection 2016.

11.

Expert Nordic perspectives on the potential of novel inhalers to overcome unmet needs in the management of obstructive lung disease.

Løkke A, Ahlbeck L, Bjermer L, Mortensen J, Østrem A, Pasternack I, Safioti G, Torvinen S.

Eur Clin Respir J. 2015 Dec 16;2:29445. doi: 10.3402/ecrj.v2.29445. eCollection 2015.

12.

The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.

Darbà J, Ramírez G, Sicras A, Francoli P, Torvinen S, Sánchez-de la Rosa R.

Int J Chron Obstruct Pulmon Dis. 2015 Oct 29;10:2335-45. doi: 10.2147/COPD.S90155. eCollection 2015.

13.

Biosimilars Entry And Price Development In Europe.

Dacheva E, Plich A, Torvinen S.

Value Health. 2015 Nov;18(7):A531. doi: 10.1016/j.jval.2015.09.1654. Epub 2015 Oct 20. No abstract available.

14.

Updated Medication Costs From A Real-Life Cost-Effectiveness Evaluation Of Budesonide/Formoterol Maintenance And Reliever Therapy In Asthma Maintenance And Reliever Therapy In Asthma.

Medin E, Safioti G, Lindqvist F, Torvinen S.

Value Health. 2015 Nov;18(7):A500. doi: 10.1016/j.jval.2015.09.1413. Epub 2015 Oct 20. No abstract available.

15.

The Potential Societal Cost Benefits Of Increasing Patient Satisfaction By Using An Inhaler With Improved Features Compared To Spiriva® Handihaler® For The Management Of Chronic Obstructive Pulmonary Disease (Copd) In The Uk.

Nicolai JL, Torvinen S, Comberiati U, Miles R, Greaney MH, Howard DJ, Plich A.

Value Health. 2015 Nov;18(7):A500. doi: 10.1016/j.jval.2015.09.1412. Epub 2015 Oct 20. No abstract available.

16.

Clinical And Economic Burden Of Asthma And Chronic Obstructive Pulmonary Disease (Copd) In Poland: Estimated Impact Of Poor Inhalation Technique With Inhaled Corticosteroid And Long-Acting Beta Agonist Fixed-Dose Combinations.

Bijos P, Kaczynski J, Torvinen S, Lenarczyk E, Wrona W, Plich A, Lewis A, Blackney M.

Value Health. 2015 Nov;18(7):A499. doi: 10.1016/j.jval.2015.09.1408. Epub 2015 Oct 20. No abstract available.

17.

The Budget Impact Of An Inhaler With Improved Features Compared To Spiriva® Handihaler® For The Management Of Chronic Obstructive Pulmonary Disease (Copd) In The Uk: Estimated Impact On Unscheduled Healthcare Costs And Inhaler Satisfaction.

Nicolai J, Torvinen S, Howard DJ, Miles R, Greaney MH, Comberiati U, Plich A.

Value Health. 2015 Nov;18(7):A497. doi: 10.1016/j.jval.2015.09.1393. Epub 2015 Oct 20. No abstract available.

18.

The Budget Impact Of Duoresp® Spiromax® Compared With Commonly Prescribed Dry Powder Inhalers For The Management Of Asthma And Chronic Obstructive Pulmonary Disease In Italy: Estimated Impact Of Inhalation Technique.

Torvinen S, Nicolai J, Pulimeno S, di Nola L, Bruno GM, Colombo GL, Di Matteo S, Valentino MC, Lewis A, Blackney M, Burgio L, Plich A.

Value Health. 2015 Nov;18(7):A496. doi: 10.1016/j.jval.2015.09.1391. Epub 2015 Oct 20. No abstract available.

19.

Comparative Effectiveness Analysis Of Mab In Asthma: The Importance Of Exacerbation Definition.

Torvinen S, Rémuzat C, Mzoughi O, Plich A, Toumi M.

Value Health. 2015 Nov;18(7):A495. doi: 10.1016/j.jval.2015.09.1382. Epub 2015 Oct 20. No abstract available.

20.

Preferences for Dry Powder Inhaler Attributes Among Patients With Asthma and Chronic Obstructive Pulmonary Disease From Five European Countries.

Hawken NA, Amri I, Elmoctar Neine M, Aballéa S, Torvinen S, Plich A.

Value Health. 2015 Nov;18(7):A364. doi: 10.1016/j.jval.2015.09.713. Epub 2015 Oct 20. No abstract available.

Supplemental Content

Loading ...
Support Center